Technology Vision Group Presents BioPartnering Europe's Extensive and Topical Conference Program
Technology Vision Group Presents BioPartnering Europe’s Extensive and Topical Conference Program
Register for BPE now and use www.biopartnering.com to set up unparalleled partnering opportunities 3 months ahead of BPE
LONDON, 4 August, 2009 – Technology Vision Group (TVG) announces an exciting and extensive program for its European partnering conference, BioPartnering Europe (BPE). BPE is the premier biotechnology partnering and networking event in Europe and will take place from 11 -14 October 2009 at the Queen Elizabeth II Conference Centre in London, UK. As usual, this year’s BPE aims not only to maximise delegates opportunities to increase their profile within the biotechnology sector, but will also examine key topics facing the industry today.
One-to-One Partnering Powered by biopartnering.com
Register for BPE now and maximize your time by using biopartnering.com to prepare almost 3-months before BPE and 1-month concluding BPE to follow up with prospects well after the conference is over. By using biopartnering.com you can network, prospect and schedule meetings before arriving in London. 90% of conference delegates rate biopartnering.com as the best conferencing software in the industry.
BPE 2009 Conference Program will Examine Key Topics Facing the Industry
• New at BPE this year is a 1-day event focusing on China
If you have a China strategy or need one, don’t miss the day to discuss your China initiatives with experts focused on China business development on 14 October 2009 after BPE.
• Leadership Sessions & Workshops
One of the most popular features of BPE are the BioPartnering Leadership Sessions, where some of the most important issues influencing the life science industry today are debated by a group of key decision makers.
This year a leadership session titled, ‘Partnering in the New Economy: The importance of leveraging unpartnered assets’, will focus on shared risk being a major driver of partnering within the pharma and biotech community in today’s economic climate. The session will be chaired by Mr. Mike Ward from BioCentury and the panellists are:
• Dr. John Goddard, Senior Vice President, Strategic Planning and Business Development, AstraZeneca
• Dr. Jeremy Levin, Senior Vice President, Strategic Transactions, Bristol-Myers Squibb Company
• Ms. Barbara Yanni, Senior Vice President & Chief Licensing Officer, Merck & Co., Inc.,
• Moderator Mr. Mike Ward, Senior Editor, Europe, BioCentury
Walk the walk with Mike Ward from BioCentury and Big Pharma Decision Makers to better understand the strategic value from partnering early and often!
• Company Presentations – LAST CHANCE TO APPLY
BPE will present over 150 of the world's most innovative companies and is one of the "must-attend" conferences for life science partnering with an international audience of more than 1200 attendees from more than 500 companies. We are still accepting applications to apply to present. Please contact Lila Taylor at firstname.lastname@example.org
"As a past presenter in TVG conferences in both the US and Europe, I make the TVG conferences a high priority because of the quality of interactions they have provided with top tier potential partners and investor groups. Presenting at TVG conferences has proven to be a very time-efficient way to meet with many potential partners." - Brent Vaughan, KineMed Inc.
• Exhibition: Spotlight on Biotechnology – SPACE AVAILABLE
The spotlight on biotechnology exhibition is new for BPE 2009 and will feature 34 innovative biotechnology companies. Be one of the first companies to exhibit at BPE!
9 of the Top 15 Pharmaceutical Companies are Already Registered to Attend BPE Join Pfizer, GlaxoSmithKline, Novartis, Sanofi-Aventis, Roche, AstraZeneca, Merck & Co., Inc., Bristol-Myers Squibb Company and Amgen, all who are confirmed participants at BPE.
Register before 1 September to receive a 20% discount with our special Early Bird Rate!
Elevate your status as a thought-leader by sponsoring a BPE 2009 panel. Contact us to become a sponsor at email@example.com.
- Ends -
About Technology Vision Group
Technology Vision Group LLC (TVG) is one of the leading networking development organizations serving the international life sciences industry. Since 1992, TVG has been developing innovative methods to help life science and associated technology companies attract partners and investors, acquire new products and technologies, and achieve a variety of other strategic business development goals.
biopartnering.com is a unique and powerful internet platform developed by TVG to enhance conference participation before, during and after BPE. Conference delegates will begin arranging meetings through biopartnering.com on 3 August 2009. biopartnering.com facilitates automated meeting scheduling and includes powerful search tools to help users identify key targets. biopartnering.com also includes time management tools that allow attendees to make the most of their time at the conference and ensure that they capitalize on all the opportunities afforded at BPE.
Confirmed Presenting Companies (as of 27 July):
Ablynx NV; Achaogen, Inc.; Addex Pharmaceuticals SA; Alchemia Pty. Ltd.; Allozyne; Ambit Biosciences; AM-Pharma B.V.; AngioChem Inc; aTyr Pharma Inc.; Auspex Pharmaceuticals; Avila Therapeutics, Inc.; Bioalliance Pharma S.A.; Biocompatibles Ltd.; Biolex Therapeutics; Biotecnol SA; Caprotec GmbH; Carolus Therapeutics, Inc.; CDG Therapeutics, Inc.; Celator Pharmaceuticals; Cerenis Therapeutics; Chaperone Technologies Inc.; Cornerstone Pharmaceuticals; Cytovance Biologics, Inc.; DBV Technologies; Debiopharm S.A.; Delcath Systems Inc; DesignMedix Inc; Emergent BioSolutions; Eureka Therapeutics, Inc.; Flamel Technologies S.A.; Heptares Therapeutics; ImmunoVaccine Technologies Inc.; iNovacia AB; Ironwood Pharmaceuticals; KAI Pharmaceuticals; KineMed, Inc.; Light Sciences Oncology, Inc; LineaGen, Inc.; Logical Therapeutics, Inc.; MicroBioChips ; Mithridion Inc; Molecular Partners AG; MorphoSys AG; Mpex Pharmaceuticals, Inc; Neogenix Oncology Corporation; Neurologix Inc.; Novacta Therapeutics; NovaMed Pharmaceuticals, Inc.; Novozymes A/S; Noxxon Pharma AG; Numerate, Inc.; Onco-D Therapeutics Inc.; Oncolytics Biotech Inc.; Otonomy, Inc; OxyPharma AB; Phylogica Limited; Pieris; Presidio Pharmaceuticals; ProteoTech Inc.; RaQualia Pharma, Inc.; Relypsa, Inc.; REVOTAR Biopharmaceuticals AG; Sangart; Savara Pharmaceuticals; Silence Therapeutics; SuperGen Inc.; Synosia Therapeutics; Syntaxin Ltd; Tetraphase Pharmaceuticals; Therosteon; Transcept Pharmaceuticals; UCB Group; Vakzine Projekt Management GmbH; ValiBIO; Vantia Ltd; VIVALIS; VLST Corp; Xention Limited; YM BioSciences Inc.; Zeta Biotech
Gold Cooley Godward Kronish LLP; Goodwin Procter LLP; Ferghana Partners Group; Taylor Wessing LLP
Silver Amgen; PharmaLegacy; Perkins Coie; Bristol-Myers Squibb Company; GlaxoSmithKline; Merck & Co.; Novartis; Pfizer Inc.; F.Hoffmann - La Roche Ltd.; Novartis; Takeda Pharmaceutical Company Limited
Conference Sponsors and Conference Supporter Genzyme Inc.; ImmuPharma PLC; Aura Capital Partners
Media Sponsors and Supporters BioBusiness; BioCentury; BioWorld Today; Business Wire; Citigate Dewe Rogerson; European BioPharmaceutical Review; FierceBiotech; Nature Publishing Group; General Biologic; GoingPublic Media AG; PharmaVentures Ltd.; Zoomedia
Global Bioscience Partnership Supporters APBio; Assobiotech; Ausbiotech; BayBio; BayBio Institute; BIOCOM; BioFlorida; BioIndustry Association; Biominas; BioMelbourne; BioNow; BioSquare; EFB; ERBI; General Biologic; LSBC; London Biotech Network; MMActiv; Oxfordshire Bioscience Network Ltd; Sweden Bio; Swiss Biotech Association; UBI France; UK Trade & Investment
Technology Vision Group LLC
Rebecca Angelos (Conference Director)
Tel: +1 831 464 4230 ext. 153
Citigate Dewe Rogerson
Helena Galilee / Amber Bielecka
Tel: +44 (0)207 282 1052 / 216 4710
Posted: August 2009